Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Investigational new drugs

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-009-9257-1PMID 19415181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma

  2008cited by this paper
• Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

  2008cited by this paper
• Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy

  2008cited by this paper
• A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b

  2008cited by this paper
• Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes

  2008cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling.

  2006cited by this paper
• Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

  2006cited by this paper
• Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results.

  2006cited by this paper
• Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

  2006cited by this paper
• A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

  2006influential reference
• Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

  2005cited by this paper
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  2005cited by this paper
• Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

  2005cited by this paper
• Berichten

  2005cited by this paper
• In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.

  2004cited by this paper
• Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results.

  2004cited by this paper
• Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• The tor pathway: a target for cancer therapy

  2004cited by this paper
• Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

  2004cited by this paper
• Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

  2004cited by this paper
• Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

  2003cited by this paper
• Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version

  2002cited by this paper
• Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

  2001cited by this paper
• Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

  2001cited by this paper
• mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

  2001cited by this paper
• Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

  2001cited by this paper
• An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice

  2001cited by this paper
• TOR, a central controller of cell growth.

  2000cited by this paper

• Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

  2023cites this paper
• TMEM97/Sigma 2 Receptor Increases Estrogen Receptor α Activity in Promoting Breast Cancer Cell Growth

  2023cites this paper
• Design, synthesis, and bioactivity evaluation of macrocyclic benzo[b]pyrido[4,3-e][1,4]oxazine derivatives as novel Pim-1 kinase inhibitors.

  2022cites this paper
• Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene.

  2020cites this paper
• Biologically active carbohydrate-containing macrocycles

  2020cites this paper
• Oral Mucosal Injury Caused by Targeted Cancer Therapies.

  2019cites this paper
• Overview of Macrocycles in Clinical Development and Clinically Used

  2017cites this paper
• In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118

  2016cites this paper
• The therapeutic potential of mTOR inhibitors in breast cancer.

  2016cites this paper
• A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.

  2015cites this paper
• Rapamycin Ester Analog CCI-779/Temsirolimus Alleviates Tau Pathology and Improves Motor Deficit in Mutant Tau Transgenic Mice

  2015cites this paper
• Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?

  2014cites this paper
• Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review

  2014cites this paper
• Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

  2014cites this paper
• Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.

  2014cites this paper
• A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

  2013cites this paper
• The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells

  2013cites this paper
• Individualising treatment choices in a crowded treatment algorithm

  2013cites this paper
• The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer

  2013cites this paper
• Differentiating mTOR inhibitors in renal cell carcinoma.

  2013cites this paper
• mTOR inhibitors in advanced breast cancer: ready for prime time?

  2013cites this paper
• Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas

  2013cites this paper
• Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0

  2013cites this paper
• Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

  2013cites this paper
• The Biological Role of PI3K Pathway in Lung Cancer

  2012cites this paper
• Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.

  2012cites this paper
• Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.

  2012cites this paper
• Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.

  2012cites this paper
• Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs

  2012cites this paper
• Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression

  2012cites this paper
• Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma

  2012cites this paper
• Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors

  2012cites this paper
• Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment

  2012cites this paper
• The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.

  2012cites this paper
• Erratum to: A Simple and Sensitive LC–MS/MS Method for Simultaneous Determination of Temsirolimus and Its Major Metabolite in Human Whole Blood

  2012cites this paper
• Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition

  2012cites this paper
• mTOR inhibitors in breast cancer: a systematic review.

  2012cites this paper
• mTOR inhibitors in advanced renal cell carcinoma.

  2011cites this paper
• New Developments in Mammalian Target of Rapamycin Inhibitors for the Treatment of Sarcoma

  2011cites this paper
• Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.

  2011cites this paper
• Selecting multimodal therapy for rhabdomyosarcoma

  2010cites this paper
• Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.

  2009cites this paper